{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:45:01Z","timestamp":1785879901633,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF23OC0081557"],"award-info":[{"award-number":["NNF23OC0081557"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R236-A18850"],"award-info":[{"award-number":["R236-A18850"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["2034\\u201300406B"],"award-info":[{"award-number":["2034\\u201300406B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008052","name":"Alfonso Mart\u00edn Escudero Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008963","name":"Spanish Society of Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009898","name":"Beckett Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009898","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejca.2026.116872","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:43:32Z","timestamp":1780674212000},"page":"116872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Progression risk among responders to PD-1\/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC"],"prefix":"10.1016","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3536-5523","authenticated-orcid":false,"given":"Rikke","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Syberg","family":"Jespersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5984-1793","authenticated-orcid":false,"given":"Mario","family":"Presti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1331-061X","authenticated-orcid":false,"given":"Birgitte","family":"Bjornhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2513-6989","authenticated-orcid":false,"given":"Anne-Cathrine","family":"\u00d8stby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kirstine Moeller","family":"Darras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7816-3294","authenticated-orcid":false,"given":"Yago","family":"Garitaonaindia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-273X","authenticated-orcid":false,"given":"Christina Halgaard","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8179-7108","authenticated-orcid":false,"given":"Malene St\u00f8chkel","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-3561","authenticated-orcid":false,"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0564-146X","authenticated-orcid":false,"given":"Rasmus Blechingberg","family":"Friis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Mahncke","family":"Guldbrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2905-5342","authenticated-orcid":false,"given":"Jon R\u00f8ikj\u00e6r","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4967-0772","authenticated-orcid":false,"given":"Andreas","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira Schreiner","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5412-9246","authenticated-orcid":false,"given":"Jesper Andreas","family":"Palshof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4402-9281","authenticated-orcid":false,"given":"Troels Holz","family":"Borch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Lykkegaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8276-4335","authenticated-orcid":false,"given":"Soeren","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Viggo","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziza","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9529-4870","authenticated-orcid":false,"given":"Ane Bundsbaek","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Meldgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Gr\u00f8nbech","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawez","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam Andrzej","family":"Luczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine","family":"Wahlstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0310-1044","authenticated-orcid":false,"given":"Daniela","family":"Zitnjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-6037","authenticated-orcid":false,"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4442-0535","authenticated-orcid":false,"given":"Niels","family":"Fristrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-5781","authenticated-orcid":false,"given":"Charlotte","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3363-3256","authenticated-orcid":false,"given":"Gitte Fredberg","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-9826","authenticated-orcid":false,"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-8662","authenticated-orcid":false,"given":"Mette","family":"Poehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-9232","authenticated-orcid":false,"given":"Eva","family":"Ellebaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-9752","authenticated-orcid":false,"given":"Marco","family":"Donia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116872_bib1","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1007\/s00262-023-03441-3","article-title":"The landscape of objective response rate of anti-PD-1\/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating [Internet]","volume":"72","author":"Mao","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2026.116872_bib2","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2021 50% [Internet]","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116872_bib3","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial [Internet]","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116872_bib4","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma [internet]","author":"Wolchok","year":"2024","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116872_bib5","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study [Internet]","volume":"41","author":"De Castro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116872_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.02.017","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial\u2606 [Internet]","author":"Choueiri","year":"2026","journal-title":"Ann Oncol 0"},{"issue":"1","key":"10.1016\/j.ejca.2026.116872_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41416-024-02895-1","article-title":"Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study [Internet]","volume":"132","author":"Hektoen","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116872_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102450","article-title":"Nationwide real-world outcomes of trial eligible and trial ineligible patients with metastatic renal cell carcinoma treated with nivolumab plus Ipilimumab [Internet]","volume":"23","author":"Jespersen","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2026.116872_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.26641","article-title":"Long-term survival in patients with advanced melanoma [Internet]","volume":"7","author":"van Not","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2026.116872_bib10","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ejca.2009.04.016","article-title":"LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951) [Internet]","volume":"45","author":"Agarwala","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116872_bib11","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1200\/JCO.2000.18.22.3782","article-title":"Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials [Internet]","volume":"18","author":"Manola","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116872_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eururo.2023.01.001","article-title":"Outcomes for international metastatic renal cell carcinoma database consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma [Internet]","volume":"84","author":"Ernst","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2026.116872_bib13","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1016\/j.cllc.2023.04.010","article-title":"Brief report: predictive value of pd-l1 expression in non\u2013small-cell lung cancer - should we set the bar higher for monotherapy? [Internet]","volume":"24","author":"Nikolic","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116872_bib14","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [Internet]","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116872_bib15","doi-asserted-by":"crossref","first-page":"10928","DOI":"10.1136\/jitc-2024-010928","article-title":"Society for immunotherapy of cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols [Internet]","volume":"13","author":"Cottrell","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116872_bib16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors [Internet]","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116872_bib17","doi-asserted-by":"crossref","first-page":"43876","DOI":"10.2340\/1651-226X.2025.43876","article-title":"Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years? [Internet]","volume":"64","author":"Decruyenaere","year":"2025","journal-title":"Acta Oncol (Madr)"},{"issue":"1979","key":"10.1016\/j.ejca.2026.116872_bib18","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1126\/science.287.5462.2398","article-title":"When an entire country is a cohort [Internet]","volume":"287","author":"Frank","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejca.2026.116872_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040296","article-title":"The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies [Internet]","volume":"4","author":"Von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2026.116872_bib20","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW) [Internet]","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116872_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.101943","article-title":"The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients [Internet]","volume":"73","author":"Ellebaek","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.ejca.2026.116872_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113476","article-title":"PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma [Internet]","volume":"198","author":"Ellebaek","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116872_bib23","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1016\/j.annonc.2024.08.1177","article-title":"1109P Association of clinical features with long-term survival in patients with melanoma who responded to distinct checkpoint inhibitors [Internet]","volume":"35","author":"Ellebaek","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116872_bib24","unstructured":"Sample-size formula for the proportional-hazards regression model - PubMed [Internet][cited 2025 Nov 29] Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/6354290\/\u3009."},{"key":"10.1016\/j.ejca.2026.116872_bib25","unstructured":"survminer R package: Survival Data Analysis and Visualization - Easy Guides - Wiki - STHDA [Internet][cited 2021 Mar 5] Available from: \u3008http:\/\/www.sthda.com\/english\/wiki\/survminer-r-package-survival-data-analysis-and-visualization\u3009."},{"key":"10.1016\/j.ejca.2026.116872_bib26","unstructured":"Therneau T.M., Grambsch P.M.: A Package for Survival Analysis in S, version 2.38 [Internet]. Modeling Survival Data: Extending the Cox Model, 2000[cited 2025 Sep 4] Available from: \u3008http:\/\/cran.r-project.org\/package=survival\u3009."},{"key":"10.1016\/j.ejca.2026.116872_bib27","unstructured":"CRAN: Package survivalAnalysis [Internet][cited 2025 Sep 4] Available from: \u3008https:\/\/cran.r-project.org\/web\/packages\/survivalAnalysis\/index.html\u3009."},{"key":"10.1016\/j.ejca.2026.116872_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v057.i12","article-title":"Building bivariate tables: the comparegroups package for R [Internet]","volume":"57","author":"Subirana","year":"2014","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ejca.2026.116872_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma. [Internet]","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116872_bib30","doi-asserted-by":"crossref","unstructured":"Weberpals J., Jansen L., Silversmit G., et al: Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients [Internet]. Clin Epidemiol 10:1109\u20131125, 2018[cited 2025 Sep 4] Available from: \u3008https:\/\/www.dovepress.com\/comparative-performance-of-a-modified-landmark-approach-when-no-time-o-peer-reviewed-fulltext-article-CLEP\u3009.","DOI":"10.2147\/CLEP.S160973"},{"key":"10.1016\/j.ejca.2026.116872_bib31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies [Internet]","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"key":"10.1016\/j.ejca.2026.116872_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference [Internet]","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ejca.2026.116872_bib33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies [Internet]","volume":"10","author":"Austin","year":"2010","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ejca.2026.116872_bib34","article-title":"74P Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients [Internet]","volume":"24","author":"Weitemeyer","year":"2024","journal-title":"Immuno-Oncol Technol"},{"key":"10.1016\/j.ejca.2026.116872_bib35","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/jnci\/djad081","article-title":"Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study [Internet]","volume":"115","author":"Helgadottir","year":"2023","journal-title":"JNCI Journal National Cancer Institute"},{"key":"10.1016\/j.ejca.2026.116872_bib36","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-024-05252-2","article-title":"The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy [Internet]","volume":"42","author":"Fujita","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.ejca.2026.116872_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4566","article-title":"Survival trends of men and women with metastatic clear cell renal cell carcinoma. [Internet]","volume":"39","author":"Grigg","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116872_bib38","first-page":"1","article-title":"Acquired resistance to immune checkpoint inhibitors across tumor types: a reconstructed individual patient data analysis [Internet]","author":"Garitaonaindia","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2026.116872_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmed.2025.03.010","article-title":"Acquired resistance to immunotherapy in solid tumors [Internet","author":"Verdys","year":"2025","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ejca.2026.116872_bib40","first-page":"1","article-title":"Comparison of RECIST 1.1 and iRECIST in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis [Internet]","volume":"13","author":"Park","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116872_bib41","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase i KEYNOTE-001 study [Internet]","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116872_bib42","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ijc.33926","article-title":"Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma [Internet]","volume":"150","author":"Ellebaek","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.116872_bib43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST) [Internet]","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:53:55Z","timestamp":1785876835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"alternative-id":["S0959804926006532"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116872","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progression risk among responders to PD-1\/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116872","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116872"}}